Abstract
We report a new case of therapy-related acute myeloid leukemia in a child with Langerhans cell histiocytosis. This patient was previously treated with a protocol of multidrug chemotherapy, containing a relatively low dose of etoposide (total dose of 900/m(2)). Twenty-six months after the end of the therapy, the patient returned to the hospital with fever and anemia. The white blood cell count was 53 x 10(9)/L. The bone marrow examination showed massive infiltration with French-American-British acute myeloid leukemia classification M4 blast cells. The patient did not respond to an intensive treatment with high dose ARA-C and idarubicin. He died 6 months later. The cytogenetic abnormality of the blast cells was a t(11;11)(p13 -15;q23), that has not been described before in a secondary leukemia case.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Child, Preschool
-
Chromosomes, Human, Pair 11 / genetics*
-
Cytarabine / administration & dosage
-
Drug Therapy, Combination
-
Enzyme Inhibitors / adverse effects*
-
Etoposide / administration & dosage
-
Etoposide / adverse effects*
-
Fatal Outcome
-
Histiocytosis, Langerhans-Cell / drug therapy*
-
Humans
-
Idarubicin / administration & dosage
-
Karyotyping
-
Leukemia, Myelomonocytic, Acute / chemically induced
-
Leukemia, Myelomonocytic, Acute / drug therapy
-
Leukemia, Myelomonocytic, Acute / genetics*
-
Male
-
Neoplasms, Second Primary / chemically induced
-
Neoplasms, Second Primary / genetics*
-
Nuclear Pore Complex Proteins / genetics
-
Prednisolone / administration & dosage
-
Prednisolone / therapeutic use
-
Topoisomerase II Inhibitors*
-
Translocation, Genetic*
-
Vinblastine / administration & dosage
-
Vinblastine / therapeutic use
Substances
-
Enzyme Inhibitors
-
Nuclear Pore Complex Proteins
-
Topoisomerase II Inhibitors
-
nuclear pore complex protein 98
-
Cytarabine
-
Vinblastine
-
Etoposide
-
Prednisolone
-
Idarubicin